Composition for nasal administration of insulin
Provided is an insulin-containing granulated composition for nasal administration comprising a crystalline cellulose aggregate having a specific particle diameter distribution as a carrier. Such granulated composition for nasal administration can efficiently increase a blood insulin concentration.
1. A granulated composition for nasal administration comprising powdered insulin and its carrier, aggregated crystalline cellulose, the distinguishing features of which are that the said insulin is non-solubilized, and that 90 w/w % or more of said crystalline cellulose aggregate has a cribriform particle diameter range of 10-350 μm in one part or across the whole area, and the said granulated composition has a particle diameter falling substantially within the range of that prescribed for the said crystalline cellulose aggregate.
2. The composition as described in claim 1 , in which the crystalline cellulose aggregate does not contain particles whose cribriform particle diameter substantially exceeds 150 μm.
3. The composition as described in claim 1 , in which 85 w/w % or more crystalline cellulose aggregate has a cribriform particle diameter range of 20-60 μm in one part or across the whole area.
4. The composition as described in claim 1 , having a cribriform particle diameter range distribution of:
w/w % or less of particle diameters below 25 μm,
20-60 w/w % of particle diameters of 25-38 μm,
20-60 w/w % of particle diameters greater than 38 μm and up to 53 μm, and
10 w/w % or less of particle diameters exceeding 53 μm, taking the entire particle as 100%.
5. The composition as described in claim 1 , having a crystalline cellulose density of 0.20-0.65 g/cm 3 .
6. A method for preparing a granulated composition for nasal administration, containing insulin, in which insulin and its carrier, aggregated crystalline cellulose, are homogeneously mixed in proportions of 1:2-100, and in which the said insulin is non-solubilized, and in which 90 w/w % or more of the said crystalline cellulose aggregate has a cribriform particle diameter range of 10-350 μm in one part or across the area.
7. The method as described in claim 6 , in which 85 w/w % or more of crystalline cellulose aggregate has a cribriform particle diameter range of 20-60 μm in one part or across the whole area, and does not contain particles whose cribriform particle diameter substantially exceeds 150 μm.
8. The method as described in claim 6 , wherein the composition has a cribriform particle diameter range distribution of:
10 w/w % or less of particle diameters below 25 μm,
20-60 w/w % of particle diameters of 25-38 μm,
20-60 w/w % of particle diameters greater than 38 μm and up to 53 μm, and
10 w/w % or less of particle diameters exceeding 53 μm, taking the entire particle as 100%.
9. A method of treating diabetes in which a granulated formulation comprising powdered insulin and its carrier, aggregated crystalline cellulose, the distinguishing features of which are that the said insulin is non-solubilized, and 90 w/w % or more of the said crystalline cellulose aggregate has a cribriform particle diameter range of 10-350 μm in one part or across the whole area, is sprayed into the nasal cavity of diabetes patients in a dosage that contains insulin in a sufficient amount to be an effective treatment for diabetes.
10. The therapeutic method as described in claim 9 , in which 85 w/w % or more of crystalline cellulose aggregate has a cribriform particle diameter range of 20-60 μm in one part or across the whole area, and does not contain particles whose cribriform particle diameter substantially exceeds 150 μm.
11. The therapeutic method as described in claim 9 , wherein the formulation has a cribriform particle diameter range distribution of:
10 w/w % or less of particle diameters below 25 μm,
20-60 w/w % of particle diameters of 25-38 μm,
20-60 w/w % of particle diameters greater than 38 μm and up to 53 μm, and
10 w/w % or less of particle diameters exceeding 53 μm, taking the entire particle as 100%.